Health-system and regulatory watchers brace for new FDA and HHS actions as mifepristone, vaccines, and psychedelic medicine dominate policy debate

Federal health officials and regulatory observers prepared for new actions from the FDA and Department of Health and Human Services in 2024, as debates intensified over mifepristone, vaccines, and psychedelic medicine policies. The focus follows recent Supreme Court rulings and studies affirming mifepristone’s safety and prompting calls from several state attorneys general to ease restrictions on its use, sources said.

The Food and Drug Administration’s ongoing evaluation of mifepristone, a medication approved in 2000 for medical termination of pregnancy up to 10 weeks gestation, is central to the anticipated regulatory actions in 2024. The FDA modified the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone on January 3, 2023, reducing burdens on the healthcare delivery system by removing the in-person dispensing requirement while maintaining pharmacy certification standards, according to agency records. This followed earlier relaxations in 2016, which included eliminating the need for in-person dispensing and adding pharmacy certification requirements.

Clinical data cited in court documents and independent studies show a fatality rate of five per million users, or 0.0005%, a safety profile considered better than penicillin, Viagra, and procedural abortion, according to FDA sources and clinical experts.

The Supreme Court’s February 2024 ruling in FDA v. Alliance for Hippocratic Medicine upheld the FDA’s original approval of mifepristone and its 2016 REMS modifications, affirming the agency’s regulatory authority. The decision came amid heightened scrutiny of the drug’s safety and distribution, with the court sustaining the FDA’s evidence-based approach to risk management.

A comprehensive study published January 12, 2026, in the Journal of the American Medical Association (JAMA) by researchers at Johns Hopkins University examined FDA internal communications and thousands of pages of documents spanning 2011 to 2023. The study confirmed that five pivotal regulatory decisions by the FDA aligned closely with scientific guidance from agency scientists, underscoring mifepristone’s safety profile comparable to over-the-counter pain relievers such as ibuprofen and acetaminophen. The research supports calls from attorneys general in New York, California, Massachusetts, and New Jersey, who petitioned in 2025 for the elimination of unnecessary REMS restrictions based on 25 years of safety data.

Access to mifepristone has expanded significantly since the COVID-19 pandemic, when temporary telemedicine and mail distribution allowances were introduced. The 2023 REMS modification made these changes permanent, enabling certified pharmacies to dispense the drug and broadening the range of healthcare providers authorized to administer it, including through telehealth, according to FDA and HHS officials. However, state-level restrictions remain a significant barrier. Many states have imposed additional laws and policies limiting access to mifepristone beyond federal regulations, despite the FDA’s removal of some restrictions, sources confirmed.

New York Attorney General Letitia James and her coalition argue that the current REMS program imposes burdensome restrictions without meaningfully improving patient safety. Their 2025 petition highlights the discrepancy between mifepristone’s regulatory status and its safety record, calling for reconsideration of state-level policies that continue to restrict access. The coalition’s position is supported by the extensive safety data and the FDA’s own assessments, officials said.

The FDA’s regulatory history with mifepristone includes the establishment of the initial REMS in 2011, affirmation of its necessity in 2013, and a 2016 relaxation of certain restrictions at the manufacturer’s request. In 2019, the FDA approved a generic version of mifepristone tablets, 200 mg, further expanding availability. The REMS program requires prescribers to be qualified to assess patient suitability and provide intervention for complications, mandates certification for dispensing pharmacies and prescribing clinicians, and includes mandatory patient counseling regarding treatment risks.

On September 19, 2025, Health and Human Services Secretary and FDA Commissioner Dr. Marty Makary addressed a letter to 22 Republican attorneys general, stating that the FDA is undertaking “its own assessment of the evidence, including real-world outcomes and data” on mifepristone safety and efficacy. The administration emphasized its commitment to ensuring that “women’s health is adequately safeguarded by thoroughly probing the conditions under which mifepristone can be provided,” reflecting ongoing federal agency efforts to study the drug’s distribution and safety.

As the FDA continues its review, the agency aims to determine how mifepristone can be safely distributed while balancing access and risk management. The regulatory process is expected to influence state policies and federal guidance in 2024 and beyond, sources said, amid broader debates over vaccines and emerging psychedelic medicines that are also drawing attention from health officials and policymakers.